Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
NCT ID: NCT05867017
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2023-07-10
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetes In Relation to Hospitalized COVID-19 Patents At Assiut University Hospital
NCT05083013
Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection
NCT05897528
Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes
NCT04550403
REsearching Covid-19 Outcomes in Diabetes (RECODE)
NCT04805970
Incidence and Predictors of Acute and Chronic Complications in Patients With Diabetes and Severe COVID-19
NCT05200819
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following participants will be enrolled: 1) have had COVID-19 infection and were hospitalized and recovered, or 2) have had mild COVID-19 infection and were seen at outpatient clinics or ER and were not required to be hospitalized, or 3) have not had COVID-19 infection but were seen in outpatient clinics or ER during the same time period.
The researchers hope to learn the long-term effects of COVID-19 infection in hospitalized patients. Specifically, they will be focusing on the subsequent development of diabetes and associated metabolic disturbances, such as impaired insulin secretion and insulin resistance. A relationship between COVID-19 and diabetes needs to be investigated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Severe COVID-19 Group
Hospitalized in ICU with COVID-19 (PCR positive) and recovered
Measure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Mild COVID-19 positive Group
COVID-19 positive (by PCR) who recovered from mild COVID-19 and were seen in outpatient clinics or ER with symptoms that did not justify hospitalization.
Measure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
COVID-19 negative Group
COVID-19 negative (by PCR) and seen in outpatient clinics or ER during same time period as Groups I and II.
Measure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Took medications used to treat diabetes prior to SARS-CoV-2 infection
* History of myocardial infarction or stroke within 6 months
* History of major organ system disease prior to COVID-19 infection
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
The University of Texas Health Science Center at San Antonio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralph DeFronzo, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas Health Science Center San Antonio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Texas Diabetes Institute - University Health System
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC20220656H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.